Do biologics-naïve patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study

Clinical and Experimental Rheumatology

Volumn 29, Issue 2, 2011, Pages 314-317

  Wakabayashi, Hiroki ^a   Oka, H ^b   Nishioka, Y ^c   Hasegawa, M ^a   Sudo, A ^a   Nishioka, K ^c  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biologics na ve; Interleukins; Rheumatoid arthritis; Tocilizumab; Tumour necrosis factor inhibitors

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD PRESSURE; COMMON COLD; CYSTITIS; DISEASE ACTIVITY SCORE 28; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HUMAN; LEUKOCYTE COUNT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; TACHYCARDIA; TREATMENT RESPONSE; VERTIGO; VOMITING; AGED; BIOLOGICAL THERAPY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT FAILURE;

AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959511009     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor á monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
2. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
3. KEYSTONE EC, HARAOUI B, BYKERK VP: Role of infliximab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S200-2.
4. BATHON JM, GENOVESE MC: The Early Rheumatoid Arthritis (ERA) Trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S195-7.
5. VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make sense. Ann Rheum Dis 2003; 62: 1195-8.
6. COHEN G, COURVOISIER N, COHEN JD, ZALTNI S, SANY J, COMBE B: The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis Clin Exp Rheumatol 2005; 23: 795-800.
7. HYRICH KL, LUNT M, WATSON KD, SYMMONS DP, SILMAN AJ; BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
8. DI POI E, PERIN A, MORASSI MP, DEL FRATE M, FERRACCIOLI GF, DE VITA S: Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007; 25: 85-7.
9. HOUSSIAU FA, DEVOGELAER JP, VAN DAMME J, DE DEUXCHAISNES CN, VAN SNICK J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8.
10. MADHOK R, CRILLY A, WATSON J, CAPELL HA: Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-4.
11. KISHIMOTO T: Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8 (Suppl. 2): S2.
12. NISHIMOTO N: Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 277-81.
13. TAMURA T, UDAGAWA N, TAKAHASHI N et al.: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90: 11924-8.
14. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-9.
15. BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S164-7.